DPP‐4 inhibition and islet function

Journal of Diabetes Investigation

¹ 

关键词: Dipeptidyl peptidase‐4 inhibition;    Glucagon secretion;    Insulin secretion;   

DOI  :  10.1111/j.2040-1124.2011.00184.x

来源: Wiley

【 摘 要 】

Abstract

During recent years, dipeptidyl peptidase-4 (DPP-4) inhibition has been included in the clinical management of type 2 diabetes, both as monotherapy and as add-on to several other therapies. DPP-4 inhibition prevents the inactivation of the incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This results in stimulation of insulin secretion and inhibition of glucagon secretion, and there is also a potential β-cell preservation effect, as judged from rodent studies; that is, it might target the key islet dysfunction in the disease. In type 2 diabetes. This reduces 24-h glucose levels and reduces HbA_1c by ≈ 0.8–1.1% from baseline levels of 7.7–8.5%. DPP-4 inhibition is safe, with a very low risk for adverse events including hypoglycemia, and it prevents weight gain. The present review summarizes the studies on the influence of DPP-4 inhibition on islet function. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00184.x, 2012)

【 授权许可】

Unknown   
© 2011 Asian Association for the Study of Diabetes and Blackwell Publishing Asia Pty Ltd